Why AbbVie Is a No-Brainer Stock to Buy on the Dip [Globe and Mail, The (Toronto, Canada)]
AbbVie Inc. (ABBV)
Last abbvie inc. earnings: 5/1 07:43 am
Check Earnings Report
US:NYSE Investor Relations:
investors.abbvie.com/investor-overview
Company Research
Source: Globe and Mail, The
AbbVie 's (NYSE: ABBV) stock closed at a record high of $238.71 on Oct. 1, 2025. However, its stock has pulled back by about 13% since then. Let's see why that pullback represents a golden buying opportunity for long-term investors who can tune out the near-term noise. Image source: Getty Images. Will AI create the world's first trillionaire? Our team just released a report on the one little-known company, called an "Indispensable Monopoly" providing the critical technology Nvidia and Intel both need. Continue » Why did AbbVie's stock decline? Before its recent pullback, AbbVie's stock had doubled in value over the previous four years. That rally was mainly driven by the market's enthusiasm for its two newer immunology drugs, Skyrizi and Rinvoq, to replace the revenue lost from its former blockbuster, Humira. However, the market was also pricing in much of that future growth and assuming that Skyrizi and Rinvoq wouldn't face any significant regulatory or competitive headwin
Show less
Read more
Impact Snapshot
Event Time:
ABBV
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ABBV alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ABBV alerts
High impacting AbbVie Inc. news events
Weekly update
A roundup of the hottest topics
ABBV
News
- Erin Lichy Gets Real About Her Natrelle® Breast Augmentation [TheStreet.com]TheStreet.com
- Erin Lichy Gets Real About Her Natrelle® Breast AugmentationPR Newswire
- Haisco Enters into Exclusive License Agreement with AbbVie to Develop Novel Medicines for PainPR Newswire
- AbbVie Showcases Late-Breaking Phase 2 Data for Mirvetuximab Soravtansine-gynx (ELAHERE®) in Platinum-Sensitive Ovarian Cancer (PSOC) at SGO 2026PR Newswire
- AbbVie (ABBV) had its price target raised by Guggenheim from $242.00 to $249.00. They now have a "buy" rating on the stock.MarketBeat
ABBV
Earnings
- 2/4/26 - Miss
ABBV
Sec Filings
- 4/3/26 - Form 8-K
- 4/2/26 - Form 4
- 4/2/26 - Form 4
- ABBV's page on the SEC website